{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T08:06:48Z","timestamp":1753862808630,"version":"3.41.2"},"reference-count":18,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Preliminary data from the MorningSun study have demonstrated that outpatient subcutaneous mosunetuzumab can be safely administered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>This publication describes how community centers in the MorningSun phase 2 study of outpatient subcutaneous mosunetuzumab in B\u2010cell non\u2010Hodgkin lymphomas prepared workflow and logistics (staff coordination, practice networks, and patient support) to monitor patients for cytokine release syndrome (CRS) and other toxicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Ten investigators at US community practice study sites (one rural, seven urban, and two rural\/urban) were interviewed between January 12 and February 22, 2024. Interview transcripts were analyzed qualitatively to identify key themes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prior to the study, 7\/10 had limited\/no experience administering bispecific antibodies for lymphoma. Regarding preparation before treatment, staff education was the most frequent need (7\/10). All sites provided in\u2010service training for staff involved with treatment administration. Most respondents (6\/10) had multidisciplinary plans and agreed these eased logistical concerns. Out of hours, patients either called the triage team, a dedicated on\u2010call number, the physician, or the emergency department. Most practices had preexisting relationships with hospitals for CRS management. All practices established methods for outpatient CRS monitoring; patient education and caregivers played important roles, and all respondents encouraged patients to use self\u2010monitoring devices. Each community practice had different workflow and logistics based on their setting and infrastructure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Community practices can leverage other sites' experiences and adopt an individualized approach to implementing bispecific antibodies safely and efficiently. Designating a physician champion could provide a local resource to address staff questions and concerns.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70936","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:05:00Z","timestamp":1748415900000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the <scp>MorningSun<\/scp> Study Investigators"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6985-6979","authenticated-orcid":false,"given":"Tara","family":"Graff","sequence":"first","affiliation":[{"name":"Mission Cancer and Blood  Des Moines Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Flinn","sequence":"additional","affiliation":[{"name":"Tennessee Oncology\/OneOncology  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-6115","authenticated-orcid":false,"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute  Eugene Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Liu","sequence":"additional","affiliation":[{"name":"Alaska Oncology &amp; Hematology LLC  Anchorage Alabama USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand M.","family":"Anz","sequence":"additional","affiliation":[{"name":"Tennessee Oncology\/OneOncology  Chattanooga Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitul","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists  Gainesville Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-7877","authenticated-orcid":false,"given":"Ayed","family":"Ayed","sequence":"additional","affiliation":[{"name":"Cancer Specialists of North Florida  Jacksonville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Zuniga","sequence":"additional","affiliation":[{"name":"New York Cancer &amp; Blood Specialists  Port Jefferson New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Hai","family":"Mansoor","sequence":"additional","affiliation":[{"name":"Kaiser Permanente  Portland Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourenia M.","family":"Cassoli","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Wu","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prachi","family":"Jani","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana M. L.","family":"Biondo","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Lin","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Burke","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153794"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_2_11_7_1","unstructured":"U.S. Food and Drug Administration \u201cMosunetuzumab Prescribing Information \u201daccessed November 18 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761263s000lbl.pdf."},{"key":"e_1_2_11_8_1","unstructured":"U.S. Food and Drug Administration \u201cFDA Grants Accelerated Approval to Epcoritamab\u2010Bysp for Relapsed or Refractory Follicular Lymphoma \u201daccessed November 18 2024 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010epcoritamab\u2010bysp\u2010relapsed\u2010or\u2010refractory\u2010follicular\u2010lymphoma#:~:text=On%20June%2026%2C%202024%2C%20the more%20lines%20of%20systemic%20therapy."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050355"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.005"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009260"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173949"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177917"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.333"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01664-z"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002056"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T07:30:51Z","timestamp":1749799851000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/cam4.70936"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70936","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"2025-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70936"}}